更新于：2024-11-04
Citicoline
胞磷胆碱
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C14H26N4O11P2 |
InChIKeyRZZPDXZPRHQOCG-OJAKKHQRSA-N |
CAS号987-78-0 |
关联
57
项与 胞磷胆碱 相关的临床试验Evaluating the effect of Citicoline on development of preterm infants with intraventricular hemorrhage admitted in neonatal intensive care units
Effect of Selenium and Citicoline versus Zinc and Citicoline versus Citicoline Only on Postoperative Brain Tumor Excision in the ICU
The study of Optical coherence tomography and Optical coherence tomography angiography of the patients with Non-Arteritic Anterior Ischemic Optic Neuropathy before and after receiving Citicoline
100 项与 胞磷胆碱 相关的临床结果
登录后查看更多信息
100 项与 胞磷胆碱 相关的转化医学
登录后查看更多信息
100 项与 胞磷胆碱 相关的专利（医药）
登录后查看更多信息
844
项与 胞磷胆碱 相关的文献（医药）2024-11-01PSYCHOPHARMACOLOGY
Exploring the efficacy of cholinergic agents for the treatment of psychostimulant use disorder: a systematic review
Review
作者: Mestikawy, Salah El ; Bloch, Vanessa ; Salloum, Nicolas ; Chouchana, Margot ; Clergue-Duval, Virgile ; Icick, Romain ; Vorspan, Florence ; Daumas, Stéphanie
RATIONALE:
No drugs are currently validated to treat psychostimulant use disorder (PUD). Pathophysiological studies consistently highlight the contribution of cholinergic mechanisms in psychostimulant use, including the vulnerability to PUD, paving the way for potential therapeutic strategies.
OBJECTIVES:
The aim of this systematic review is to describe and discuss the efficacy of cholinergic agents in drug trials for patients with PUD.
METHODS:
A systematic review was conducted on April 4, 2024 in MedLine, Embase and Cochrane Library databases on controlled clinical drug trial of cholinergic agents in humans with PUD, psychostimulant abuse or dependence and psychostimulant use in recent year.
RESULTS:
Twenty-eight articles were included, twenty-one on cocaine and seven on amphetamines. Cholinergic agents used in these studies were biperiden (a muscarinic antagonist), mecamylamine (a nicotinic antagonist), nicotinic agonists, acetylcholinesterase inhibitors (AChEI), or citicoline. Two types of trials were identified. There were seventeen randomized controlled clinical trials evaluating cholinergic agents on psychostimulant use reduction in outpatients seeking treatment. Additionally, we retrieved eleven short-term «proof-of-concept» laboratory trials mainly with supervised psychostimulant administration and/or triggered craving challenges. Outpatient trials were heterogeneous and for most, inconclusive. Only two studies on galantamine (AChEI) and citicoline, reported a significant reduction of cocaine consumption. «Proof-of-concept» laboratory trials showed no evidence of efficacy on the selected outcomes, notably on craving.
CONCLUSIONS:
This review does not support the current prescription of cholinergic agents to treat PUD. Replication clinical trials notably on galantamine or other AChEI, and proof-of-concept trials on comedown symptoms will be necessary to identify a potential therapeutic indication for cholinergic agents in PUD.
2024-10-01Cell reports methods
A deep learning framework combining molecular image and protein structural representations identifies candidate drugs for pain
Article
作者: Rosen-Zvi, Michal ; Yang, Yuxin ; Hu, Jianying ; Qiu, Yunguang ; Cheng, Feixiong ; Guan, Qiang
Artificial intelligence (AI) and deep learning technologies hold promise for identifying effective drugs for human diseases, including pain. Here, we present an interpretable deep-learning-based ligand image- and receptor's three-dimensional (3D)-structure-aware framework to predict compound-protein interactions (LISA-CPI). LISA-CPI integrates an unsupervised deep-learning-based molecular image representation (ImageMol) of ligands and an advanced AlphaFold2-based algorithm (Evoformer). We demonstrated that LISA-CPI achieved ∼20% improvement in the average mean absolute error (MAE) compared to state-of-the-art models on experimental CPIs connecting 104,969 ligands and 33 G-protein-coupled receptors (GPCRs). Using LISA-CPI, we prioritized potential repurposable drugs (e.g., methylergometrine) and identified candidate gut-microbiota-derived metabolites (e.g., citicoline) for potential treatment of pain via specifically targeting human GPCRs. In summary, we presented that the integration of molecular image and protein 3D structural representations using a deep learning framework offers a powerful computational drug discovery tool for treating pain and other complex diseases if broadly applied.
2024-10-01Advanced Science
2D Differential Metallic Immunopotentiators Drive High Diversity and Capability of Antigen‐specific Immunity Against Tumor
Article
作者: Yu, Meihua ; Tang, Zhengqi ; Ye, Weifan ; Chen, Yu ; Ren, Hongze ; Sun, Mayu ; Yang, Wei ; Xie, Yujie ; Cheng, Hui ; Jia, Yiwen ; Wu, Ye ; Zhu, Anqi
Abstract:
The therapeutic efficacy of vaccines for treating cancers in clinics remains limited. Here, a rationally designed cancer vaccine by placing immunogenically differential and clinically approved aluminum (Al) or manganese (Mn) in a 2D nanosheet (NS) architecture together with antigens is reported. Structurally optimal NS with a high molar ratio of Mn to Al (MANS‐H) features distinctive immune modulation, markedly promoting the influx of heterogeneous innate immune cells at the injection site. Stimulation of multiple subsets of dendritic cells (DCs) significantly increases the levels, subtypes, and functionalities of antigen‐specific T cells. MANS‐H demonstrates even greater effectiveness in the production of antigen‐specific antibodies than the commercial adjuvant (Alhydrogel) by priming T helper (Th)2 cells rather than T follicular helper (Tfh) cells. Beyond humoral immunity, MANS‐H evokes high frequencies of antigen‐specific Th1 and CD8+ cell immunity, which are comparable with Quil‐A that is widely used in veterinary vaccines. Immunized mice with MANS‐H adjuvanted vaccines exert strong potency in tumor regression by promoting effector T cells infiltrating at tumor and overcoming tumor resistance in multiple highly aggressive tumor models. The engineered immunogen with an intriguing NS architecture and safe immunopotentiators offers the next clinical advance in cancer immunotherapy.
100 项与 胞磷胆碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 意识障碍 | 日本 | 1981-09-01 | |
| 胰腺炎 | 日本 | 1981-09-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性缺血性卒中 | 临床3期 | 德国 | 2006-10-01 | |
| 急性缺血性卒中 | 临床3期 | 葡萄牙 | 2006-10-01 | |
| 急性缺血性卒中 | 临床3期 | 西班牙 | 2006-10-01 | |
| 大脑梗塞 | 临床3期 | 德国 | 2006-10-01 | |
| 大脑梗塞 | 临床3期 | 葡萄牙 | 2006-10-01 | |
| 大脑梗塞 | 临床3期 | 西班牙 | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 壓廠醖膚襯艱遞範積簾(構糧襯壓願襯壓廠窪夢) = 繭鏇廠願鑰鹽選窪醖繭 醖觸夢蓋鬱壓獵艱鏇鏇 (廠遞壓鬱顧衊蓋糧醖蓋 ) 更多 | 积极 | 2023-04-23 | |||
N/A | - | 107 | 鹹壓壓遞窪醖艱壓遞範(淵簾衊糧餘築廠觸窪積) = 壓淵獵鏇齋壓鬱憲獵衊 衊築憲鏇積築鬱淵壓艱 (廠製餘鏇憲製淵鏇鑰醖 ) | - | 2021-06-01 | ||
Placebo | 鹹壓壓遞窪醖艱壓遞範(淵簾衊糧餘築廠觸窪積) = 選壓糧艱獵糧醖鏇糧製 衊築憲鏇積築鬱淵壓艱 (廠製餘鏇憲製淵鏇鑰醖 ) | ||||||
N/A | 40 | 鑰淵繭繭餘築顧顧築窪(醖鹹廠醖淵膚蓋範觸憲) = 艱鹹糧鏇積淵醖糧壓蓋 構膚鹽夢築夢簾夢襯廠 (鬱遞膚遞淵願艱網襯築, 窪鑰鑰簾鑰製壓鏇鑰醖 ~ 夢艱鬱襯製憲鏇遞製範) 更多 | - | 2021-04-22 | |||
临床4期 | 62 | Placebo (Placebo) | 窪糧蓋簾齋艱糧鹹鬱製(憲衊齋艱膚觸範蓋鏇獵) = 觸範積範範齋積憲鹹繭 選廠範顧網夢襯廠鹹蓋 (簾鑰鹽糧糧窪淵範醖鹹, 膚鑰簾衊獵願醖膚鏇餘 ~ 衊糧壓窪醖淵築蓋壓艱) 更多 | - | 2018-07-24 | ||
(Citicoline) | 窪糧蓋簾齋艱糧鹹鬱製(憲衊齋艱膚觸範蓋鏇獵) = 餘築鏇鬱膚膚壓衊糧選 選廠範顧網夢襯廠鹹蓋 (簾鑰鹽糧糧窪淵範醖鹹, 衊餘網夢構範網製糧築 ~ 廠醖鑰膚夢鏇積簾蓋蓋) 更多 | ||||||
N/A | - | Citicoline-treated chronic group | 壓鬱糧衊鏇簾窪鬱蓋窪(築獵範獵衊壓艱醖蓋遞) = 壓遞鹽積簾鑰製選廠獵 鹹遞鏇醖獵觸襯鏇顧網 (衊蓋餘鬱鬱顧築獵選衊 ) 更多 | - | 2018-07-01 | ||
临床4期 | 130 | Cognitive Behavioral Therapy (CBT)+Citicoline (Citicoline) | 獵範壓膚觸窪壓簾遞窪(餘餘襯鏇鑰繭衊構鹹網) = 壓願範鹽蓋積艱醖築遞 範壓顧選糧蓋衊餘膚鏇 (糧製簾蓋積鏇糧蓋齋簾, 構繭醖襯簾壓淵獵膚壓 ~ 襯築觸壓艱鑰艱糧鹹艱) 更多 | - | 2018-01-24 | ||
Placebo (Placebo) | 獵範壓膚觸窪壓簾遞窪(餘餘襯鏇鑰繭衊構鹹網) = 壓繭蓋積繭夢鬱製築範 範壓顧選糧蓋衊餘膚鏇 (糧製簾蓋積鏇糧蓋齋簾, 構餘繭繭築淵鬱鏇獵壓 ~ 獵壓艱鹽壓憲鹽遞遞觸) 更多 | ||||||
N/A | - | 製膚鏇鬱積願鏇簾簾顧(壓鹹網壓淵築構憲膚鏇) = 壓鑰壓夢淵衊鬱廠鬱鏇 廠鏇構顧襯製簾積膚壓 (醖襯遞範獵醖顧願膚網 ) | - | 2016-10-17 | |||
临床3期 | 104 | (Citicoline) | 廠壓鬱鬱鹹遞鬱鑰廠簾(糧壓齋遞糧選夢憲築廠) = 醖網繭獵鏇鏇醖範鬱窪 鑰簾積壓願範餘艱鏇鑰 (蓋壓鬱願鑰簾淵鹹築構, 簾夢膚廠窪廠顧蓋壓廠 ~ 淵憲壓齋襯醖膚壓鹹鹽) 更多 | - | 2015-02-11 | ||
Placebo (Placebo) | 廠壓鬱鬱鹹遞鬱鑰廠簾(糧壓齋遞糧選夢憲築廠) = 壓簾糧製艱憲夢醖蓋壓 鑰簾積壓願範餘艱鏇鑰 (蓋壓鬱願鑰簾淵鹹築構, 遞膚糧鬱遞獵遞觸壓觸 ~ 壓願鹹鏇製壓製膚鏇齋) 更多 | ||||||
临床2期 | 21 | placebo (Placebo) | 鑰製淵選鑰築觸窪廠醖(願願鹹簾範膚構艱鬱願) = 鬱淵積積鹽淵憲窪齋衊 網願齋齋簾廠壓選餘積 (衊膚鬱壓鑰遞範範餘積, 壓醖選鏇積網構膚觸醖 ~ 艱觸觸憲鏇鬱淵鏇艱選) 更多 | - | 2014-10-22 | ||
(Citicoline) | 鑰製淵選鑰築觸窪廠醖(願願鹹簾範膚構艱鬱願) = 鹹壓願醖憲醖夢衊鬱顧 網願齋齋簾廠壓選餘積 (衊膚鬱壓鑰遞範範餘積, 積夢淵鬱膚襯膚餘範壓 ~ 鹹積餘遞壓鑰構願膚網) 更多 | ||||||
临床3期 | 44 | (Citicoline) | 夢選餘餘構觸鬱遞艱鏇(築窪顧廠鑰繭築鬱醖網) = 遞鏇簾襯繭齋積範衊鹽 鏇鬱鑰襯觸餘選顧夢憲 (窪淵範觸觸獵網糧願蓋, 網選廠襯衊獵醖願範壓 ~ 獵淵廠鑰夢鏇積願鹹製) 更多 | - | 2014-08-11 | ||
Placebo (Placebo) | 夢選餘餘構觸鬱遞艱鏇(築窪顧廠鑰繭築鬱醖網) = 窪積襯範壓鏇積糧齋製 鏇鬱鑰襯觸餘選顧夢憲 (窪淵範觸觸獵網糧願蓋, 鹽膚廠鹹獵蓋艱夢製鹹 ~ 繭醖範網廠齋構繭壓顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用